Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

Marina Elena Cazzaniga, P. Pronzato, Francesco Schettini et al.|Journal of Clinical Oncology|2019

Cited by 0